Jan Tennvall
1 – 93 of 93
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE
(
- Contribution to journal › Article
- 2022
-
Mark
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
(
- Contribution to journal › Article
-
Mark
Selumetinib Plus Adjuvant Radioactive Iodine in Patients with High-Risk Differentiated Thyroid Cancer : A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)
(
- Contribution to journal › Article
-
Mark
Dosimetric quantities of neuroendocrine tumors over treatment cycles with 177Lu-DOTA-TATE
(
- Contribution to journal › Article
-
Mark
Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres
(
- Contribution to journal › Article
- 2021
-
Mark
Pituitary function after high-dose 177Lu-DOTATATE therapy and long-term follow-up
(
- Contribution to journal › Article
- 2020
-
Mark
Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines
(
- Contribution to journal › Article
- 2019
-
Mark
The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves' Disease
(
- Contribution to journal › Article
- 2018
-
Mark
Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
(
- Contribution to journal › Article
- 2017
-
Mark
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
(
- Contribution to journal › Article
- 2015
-
Mark
Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model.
(
- Contribution to journal › Article
-
Mark
Role of CD8-positive cells in radioimmunotherapy utilizing (177)Lu-mAbs in an immunocompetent rat colon carcinoma model.
(
- Contribution to journal › Article
-
Mark
Long-term retention of 177Lu/177mLu-Dotatate in patients investigated by gamma spectrometry and gamma camera imaging.
(
- Contribution to journal › Article
- 2014
-
Mark
Change in Cell Death Markers During (177)Lu-mAb Radioimmunotherapy-Induced Rejection of Syngeneic Rat Colon Carcinoma.
(
- Contribution to journal › Article
-
Mark
Sequential Radioimmunotherapy with (177)Lu- and (211)At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
-
Mark
Fellowship framgångssaga i Lund
(
- Contribution to journal › Debate/Note/Editorial
- 2013
-
Mark
The Intratumoral Distribution of Radiolabeled 177Lu-BR96 Monoclonal Antibodies Changes in Relation to Tumor Histology over Time in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
-
Mark
Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.
(
- Contribution to journal › Article
-
Mark
Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases
(
- Contribution to journal › Article
- 2012
-
Mark
Repeated Radioimmunotherapy with (177)Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
-
Mark
Pattern of antigen expression in metastases after radioimmunotherapy of a syngeneic rat colon carcinoma utilizing the BR96 antibody.
(
- Contribution to journal › Article
-
Mark
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
(
- Contribution to journal › Article
- 2011
-
Mark
Different toxicity profiles for drug-versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model
(
- Contribution to journal › Article
-
Mark
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds
(
- Contribution to journal › Article
-
Mark
Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.
(
- Contribution to journal › Article
- 2010
-
Mark
Vandetanib In Locally Advanced Or Metastatic Differentiated Thyroid Cancer (Papillary Or Follicular; Dtc): A Randomized, Double-Blind Phase Ii Trial
2010) 35th European-Society-for-Medical-Oncology (ESMO) Congress In Annals of Oncology 21. p.315-315(
- Contribution to journal › Published meeting abstract
-
Mark
90Y Bremsstrahlung Imaging for Absorbed-Dose Assessment in High-Dose Radioimmunotherapy.
(
- Contribution to journal › Article
-
Mark
High-Dose Radioimmunotherapy Combined With Extracorporeal Depletion in a Syngeneic Rat Tumor Model
(
- Contribution to journal › Article
-
Mark
Toxicity-Reducing Potential of Extracorporeal Affinity Adsorption Treatment in Combination With the Auristatin-Conjugated Monoclonal Antibody BR96 in a Syngeneic Rat Tumor Model
(
- Contribution to journal › Article
-
Mark
Lu-177-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy
(
- Contribution to journal › Article
- 2009
-
Mark
Peptide Receptor Radionuclide Therapy (PRRT) Using 177Lu-DOTATATE: Early Clinical and Dosimetric Results
2009) 6th Annual Conference of the European-Neuroendocrine-Tumor-Society In Neuroendocrinology 90(1). p.44-44(
- Contribution to journal › Published meeting abstract
-
Mark
High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
(
- Contribution to journal › Article
-
Mark
Development and evaluation of a pharmacokinetic model for prediction of radioimmunotherapy based on pretherapy data.
(
- Contribution to journal › Article
- 2008
-
Mark
Guidelines for radioiodine therapy of differentiated thyroid cancer
(
- Contribution to journal › Scientific review
-
Mark
Peptide receptor radionuclide therapy (PRRT) using Lu-177-Dotatate: Early clinical and dosimetric results
2008) Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 23(4). p.524-525(
- Contribution to journal › Published meeting abstract
-
Mark
High dose radioimmunotherapy combined with extracorporeal depletion in syngeneic rat tumor model. Evaluation of toxicity, therapeutic effect, and tumor model
2008) Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 23(4). p.517-517(
- Contribution to journal › Published meeting abstract
-
Mark
Evaluation of toxicity-reducing potential of ECAT in combination with drug-conjugated mAb BR96
2008) Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 23(4). p.520-520(
- Contribution to journal › Published meeting abstract
-
Mark
Consequences of Inadvertent Radioiodine Treatment of Graves' Disease and Thyroid Cancer in Undiagnosed Pregnancy. Can We Rely on Routine Pregnancy Testing?
(
- Contribution to journal › Article
- 2007
-
Mark
EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with (90)Y-radiolabelled ibritumomab tiuxetan (Zevalin).
(
- Contribution to journal › Article
-
Mark
Improved tumor targeting and decreased normal tissue accumulation through extracorporeal affinity adsorption in a two-step pretargeting strategy
(
- Contribution to journal › Article
-
Mark
EANM procedure guideline for (32)P phosphate treatment of myeloproliferative diseases.
(
- Contribution to journal › Article
-
Mark
Combined flow cytometry and confocal laser scanning microscopy for evaluation of BR96 antibody cancer cell targeting and internalization.
(
- Contribution to journal › Article
-
Mark
Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray"
(
- Contribution to journal › Scientific review
-
Mark
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
(
- Contribution to journal › Article
-
Mark
Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion.
(
- Contribution to journal › Article
-
Mark
Biocompatibility of a novel avidin-agarose adsorbent for extracorporeal removal of redundant radiopharmaceutical from the blood.
(
- Contribution to journal › Article
-
Mark
Targeted therapy in nuclear medicine current status and future prospects
(
- Contribution to journal › Article
-
Mark
A nonsurgical technique for blood access in extracorporeal affinity adsorption of antibodies in rats.
(
- Contribution to journal › Article
- 2006
-
Mark
Clinical applications of newer radionuclide therapies
(
- Contribution to journal › Article
-
Mark
Rat testis as a radiobiological in vivo model for radionuclides.
(
- Contribution to journal › Article
- 2005
-
Mark
Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
(
- Contribution to journal › Article
-
Mark
Concurrent radiotherapy and tumor targeting with 111In-HMFG1-F(ab')2 in patients with MUC1-positive non-small cell lung cancer.
(
- Contribution to journal › Article
-
Mark
Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab.
(
- Contribution to journal › Article
-
Mark
Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling.
(
- Contribution to journal › Article
-
Mark
Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
(
- Contribution to journal › Article
-
Mark
A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and (90)y-labeled rituximab in patients with refractory B-cell lymphoma.
(
- Contribution to journal › Article
- 2004
-
Mark
Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients
(
- Contribution to journal › Article
-
Mark
DNA ploidy, S-phase fraction and associations with 2-18F-fluoro-deoxy-2-D-glucose positron emission tomography findings before and during therapy of head and neck squamous cell carcinoma.
(
- Contribution to journal › Article
-
Mark
Blood pharmacokinetics of various mabs labeled with a new tri-chelating reagent for simultaneous conjugation with DOTA and biotin prior to radiolabeling
2004) 10th Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 19(4). p.540-541(
- Contribution to journal › Published meeting abstract
- 2003
-
Mark
Change in Tumor-absorbed Dose due to Decrease in Mass during Fractionated Radioimmunotherapy in Lymphoma Patients.
(
- Contribution to journal › Article
-
Mark
Biotinylation, pharmacokinetics, and extracorporeal adsorption of humanized MAb 111In-MN14 using an avidin-affinity column in rats.
(
- Contribution to journal › Article
-
Mark
Tumour therapy with radionuclides: assessment of progress and problems
(
- Contribution to journal › Scientific review
- 2002
-
Mark
Single tumor cell uptake and dosimetry of technetium-99m Fab ' anti-CD22 in low-grade B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery.
(
- Contribution to journal › Article
-
Mark
FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma.
(
- Contribution to journal › Article
-
Mark
Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotin.
(
- Contribution to journal › Article
-
Mark
Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry.
(
- Contribution to journal › Article
-
Mark
A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin (R)) on a named patient basis in Sweden
(
- Contribution to journal › Article
-
Mark
131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.
(
- Contribution to journal › Article
- 2001
-
Mark
A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus
(
- Contribution to journal › Article
-
Mark
Prognostic value of histopathological response to radiotherapy and microvessel density in oral squamous cell carcinomas
(
- Contribution to journal › Article
- 2000
-
Mark
PET-verksamhet i Lund - några upplysningar
(
- Contribution to journal › Article
-
Mark
Extracorporeal techniques in radioimmunotherapy
2000) p.223-243(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 1999
-
Mark
Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas
(
- Contribution to journal › Article
-
Mark
Hyperthyroidism after surgery for primary hyperparathyroidism
(
- Contribution to journal › Article
- 1997
-
Mark
Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody
(
- Contribution to journal › Article
-
Mark
Early prediction of treatment outcome in head and neck cancer with 2-18FDG PET
(
- Contribution to journal › Article
-
Mark
Malignant struma ovarii' with peritoneal dissemination
(
- Contribution to journal › Letter
-
Mark
Sestamibi versus thallium subtraction scintigraphy in parathyroid localization : a prospective comparative study in patients with predominantly mild primary hyperparathyroidism
(
- Contribution to journal › Article
- 1996
-
Mark
Extracorporeal immunoadsorption from whole blood based on the avidin-biotin concept. Evaluation of a new method
(
- Contribution to journal › Article
-
Mark
Biodistribution and pharmacokinetics of 125I/131I pair-labelled biotinylated chimeric BR96 in colon carcinoma isografted rats
(
- Contribution to journal › Article
- 1995
-
Mark
A Phase I/II Evaluation of Metoclopramide as a Radiosensitiser in Patients with Inoperable Squamous Cell Carcinoma of the Lung
(
- Contribution to journal › Article
-
Mark
Enhanced radioimmunotargeting of 125I-labeled L6-biotin monoclonal antibody (MAb) by combining preload of cold L6 MAb and subsequent immunoadsorption in rats
(
- Contribution to journal › Article
-
Mark
Determination of nonendemic nasopharyngeal carcinoma by in situ hybridization for Epstein-Barr virus EBER1 RNA: sensitivity and specificity in cervical node metastases.
(
- Contribution to journal › Article
- 1994
-
Mark
A general extracorporeal immunoadsorption method to increase tumor-to-tissue ratio
(
- Contribution to journal › Article
-
Mark
Improving radioimmunotargeting of tumors: the impact of preloading unlabeled L6 monoclonal antibody on the biodistribution of 125I-L6 in rats
(
- Contribution to journal › Article
-
Mark
Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption
(
- Contribution to journal › Scientific review
-
Mark
Extracorporeal immunoadsorption of 125I-labeled monoclonal antibody L6.
(
- Contribution to journal › Article
- 1993
-
Mark
DNA analysis as a predictor of the outcome of induction chemotherapy in advanced head and neck carcinomas
(
- Contribution to journal › Article
-
Mark
Improving radioimmonotargeting of tumors. Variation in the amount of L6 MAb administered, combined with an immunoadsorption system (ECIA)
(
- Contribution to journal › Article
-
Mark
Radioimmunotherapy dosimetry--a review
(
- Contribution to journal › Scientific review
-
Mark
T3N0 glottic carcinoma: DNA S-phase as a predictor of the outcome after radiotherapy
(
- Contribution to journal › Article
- 1992
-
Mark
Thallium-technetium subtraction scintigraphy of enlarged parathyroid glands after calcitonin stimulation of parathyroid hormone secretion
(
- Contribution to journal › Article